Daily Respiratory Research Analysis
Real-world data confirm that nirsevimab substantially reduces RSV-related hospitalizations and ICU admissions in infants across multiple countries. A randomized trial shows early nebulized heparin improves ventilator- and ICU-free days after smoke inhalation injury, while a validated lung ultrasound criterion set (LUS-ILD-24) reliably detects interstitial lung disease in systemic sclerosis and inflammatory myopathy with high sensitivity/specificity.
Summary
Real-world data confirm that nirsevimab substantially reduces RSV-related hospitalizations and ICU admissions in infants across multiple countries. A randomized trial shows early nebulized heparin improves ventilator- and ICU-free days after smoke inhalation injury, while a validated lung ultrasound criterion set (LUS-ILD-24) reliably detects interstitial lung disease in systemic sclerosis and inflammatory myopathy with high sensitivity/specificity.
Research Themes
- RSV prevention and real-world effectiveness
- Acute inhalation injury management with inhaled anticoagulants
- Point-of-care imaging for early ILD detection in rheumatic disease
Selected Articles
1. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.
Across 27 observational studies from five countries, nirsevimab markedly reduced RSV-related hospitalizations (OR ≈ 0.17), ICU admissions, and shortened hospital length of stay in infants within one RSV season. Benefits held across programmatic rollouts, supporting population-level effectiveness beyond trials.
Impact: Provides robust policy-grade evidence that an all-infant RSV immunization strategy prevents severe disease in real-world settings. This directly informs national rollout, timing, and resource allocation.
Clinical Implications: Supports broad adoption of nirsevimab in infant immunization schedules to reduce RSV-related hospital and ICU burden. Health systems can anticipate fewer admissions and shorter stays during RSV season.
Key Findings
- Pooled real-world data showed a large reduction in RSV-related hospitalizations (OR 0.17; 95% CI 0.12–0.23).
- ICU admissions for RSV were significantly lower in nirsevimab recipients across programs.
- Length of stay was reduced (negative WMD), indicating downstream resource savings.
Methodological Strengths
- Systematic, multi-database search with prespecified outcomes and PROSPERO registration
- Random-effects meta-analysis across diverse health systems enhancing generalizability
Limitations
- Observational designs are prone to residual confounding and programmatic biases
- Heterogeneity in case definitions, testing practices, and follow-up across countries
Future Directions: Head-to-head effectiveness vs alternative prevention strategies, equity analyses in underserved populations, and cost-effectiveness modeling to optimize program design.
BACKGROUND: Nirsevimab was approved in 2023, and implemented in all-infant immunisation programmes in several high-income countries to prevent lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV). Knowledge of real-world effectiveness of broad nirsevimab programmes is crucial to validate the benefits observed in clinical trials and guide immunisation policy. We assessed the real-world effectiveness of nirsevimab in populations where infant immunisation programmes were introduced. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, Web of Science, Scopus, Global Health, and medRxiv from Jan 1, 2023, to Feb 25, 2025, to identify observational studies of immunisation programmes for infants aged 2 years or younger in routine clinical practice reporting original data for the real-world effectiveness of nirsevimab. The primary analysis focused on infants aged 12 months or younger. Pooled analyses were done with inverse-variance random-effects models for RSV-related hospital admissions, intensive care unit (ICU) admissions, and RSV-related LRTI incidence. For length of hospital stay, we used a restricted maximum likelihood random-effects model to estimate the weighted mean difference (WMD) in days between the nirsevimab and control groups. This study is registered with PROSPERO (CRD42024628782). FINDINGS: We identified and screened 1238 records, of which 32 cohort and case-control studies from five countries (France, Italy, Luxembourg, Spain, and the USA) were included in the systematic review and 27 of them were included in the meta-analysis. Nirsevimab was associated with a lower odds of RSV-related hospitalisation (odds ratio 0·17; 95% CI 0·12-0·23; I
2. Effect of early administration of inhaled heparin on outcomes of smoke inhalation injury: A randomized controlled trial.
In adults with smoke inhalation injury, early nebulized heparin increased ventilator-free and ICU-free days and improved oxygenation. The time-to-weaning from mechanical ventilation was significantly accelerated.
Impact: This is a randomized trial targeting a common, morbid ICU problem with a simple, scalable intervention that improved patient-centered outcomes.
Clinical Implications: Consider protocolized early nebulized heparin for smoke inhalation injury to hasten ventilator liberation and ICU throughput, with careful bleeding risk assessment.
Key Findings
- Nebulized heparin increased ventilator-free days at 28 days (adjusted P = 0.046).
- Cumulative incidence of successful weaning from mechanical ventilation was higher (P = 0.007).
- ICU-free days increased (P = 0.015) and PaO2/FiO2 improved compared with control.
Methodological Strengths
- Randomized allocation within 24 hours of injury with protocolized dosing
- Adjusted analyses for burn size and time-to-randomization; clinically meaningful endpoints
Limitations
- Modest sample size and potential lack of blinding
- Single-condition context; bleeding outcomes and safety profile not fully detailed in abstract
Future Directions: Larger multicenter trials, safety/bleeding surveillance, and evaluation of dose-finding and co-interventions (e.g., mucolytics, bronchoscopy).
BACKGROUND: The present study aimed to examine the effects of early administration of inhaled heparin on the outcome of smoke inhalation injury. METHODS: Eighty-eight adults suffering smoke inhalation injury within 24 h were randomized to receive 5000 IU of heparin (n = 44) or normal saline (n = 44) by nebulization every 4 h until successful extubation or death, up to a maximum of 14 days. The primary outcome was ventilator-free days (VFDs) and alive at 28 days. The secondary outcomes included the intensive care unit (ICU)-free days and alive at 28 days, change in the PaO RESULTS: When adjusted to the burn area and burn-to-randomization time, inhaled heparin was associated with more VFDs (P =.046) and a higher cumulative incidence of weaning from mechanical ventilation over time (P =.007). Patients receiving inhaled heparin had more ICU-free days (P =.015), higher PaO CONCLUSIONS: The early administration of inhaled heparin to patients suffering smoke inhalation injury was associated with more VFDs and enhanced weaning from mechanical ventilation. Inhaled heparin was also associated with more ICU-free days, higher PaO
3. Validation of Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.
In 95 patients with SSc or inflammatory myopathy, the LUS-ILD-24 criteria detected CT-confirmed ILD with sensitivity ~92–96% and specificity ~83–86%, showing near-perfect inter/intrarater agreement. LUS severity correlated with CT severity and inversely with DLCO and FVC.
Impact: Offers a practical, low-radiation screening tool to triage and monitor rheumatic disease patients at risk for ILD, potentially expediting diagnosis and reducing CT utilization.
Clinical Implications: Integrate LUS-ILD-24 into screening algorithms for SSc/IM to prioritize CT and PFTs, track disease severity, and enable earlier antifibrotic or immunomodulatory therapy.
Key Findings
- Sensitivity 92.4–95.5% and specificity 82.8–86.2% for CT-confirmed ILD across three blinded readers.
- Near-perfect interrater (κ=0.92) and intrarater (κ=0.90–1) reliability.
- LUS severity correlated with CT severity and inversely with DLCO and FVC.
Methodological Strengths
- Blinded, multi-reader validation against CT reference standard
- Convergent validity with both imaging and physiologic (PFT) severity metrics
Limitations
- Single-cohort size (n=95) limits precision and external generalizability
- Operator dependence and equipment variability not fully addressed
Future Directions: Multicenter standardization, training curricula, and longitudinal studies to assess responsiveness to treatment and prognostic value.
OBJECTIVE: Interstitial lung disease (ILD) has a high prevalence in patients with systemic sclerosis (SSc) and inflammatory myopathy (IM), and early identification reduces associated morbidity and mortality. We previously developed lung ultrasound (LUS) interpretation criteria for ILD detection in 2020 (LUS-ILD-20) showing excellent sensitivity and specificity in patients with SSc-ILD; herein, we sought to validate a revised LUS-ILD-24 in a large cohort with SSc and IM. METHODS: Patients meeting criteria for SSc and IM, with planned computed tomography (CT) chest imaging underwent LUS imaging interpreted with LUS-ILD-24 by three blinded readers. The sensitivity and specificity for LUS-ILD detection as noted on CT was analyzed for subgroups with SSc, IM, and possible incident ILD. Inter- and intrarater agreements were calculated. Correlations between LUS-ILD-24 severity, CT imaging severity, and pulmonary function tests were assessed. RESULTS: Ninety-five patients were included in the analyses. Sensitivity and specificity for ILD detection ranged from 92.4% to 95.5% and 82.8% to 86.2% across readers with similar accuracy in all subgroups. Inter- and intrareader reliability showed near perfect agreement (κ = 0.92 and κ = 0.90 to 1, respectively). LUS severity correlated with CT imaging severity and inversely correlated with diffusion capacity for carbon monoxide and forced vital capacity. CONCLUSION: We validated our revised LUS-ILD-24 in cohorts with SSc and IM and found excellent sensitivity, specificity, and reliability for detection of ILD identified on CT imaging. LUS severity correlated with CT and pulmonary function test markers of ILD severity. Validation of the revised LUS-ILD-24 supports the implementation of LUS imaging in screening algorithms for ILD in patients with SSc and IM.